Huella
Profundice en los temas de investigación de 'Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol'. En conjunto forman una huella única.- Clasificar por
- Ponderación
- Alfabéticamente
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
ODYSSEY OUTCOMES Committees and Investigators
- University of Colorado School of Medicine
- SUNY Downstate Medicle Center
- University of Alabama at Birmingham
- Instituto Cardiovascular de Rosario
- University of Alberta
- St. Michael's Hospital
- Leiden University
- Interuniversity Cardiology Institute of the Netherlands
- Charité Universitätsmedizin
- Universidad de Santander
- Regeneron Pharmaceuticals, Inc.
- Hoechst
- University Hospitals Leuven
- Auckland District Health Board
- Université Paris Descartes
- ICMS Royal Brompton Hospital
Producción: Contribución a una revista › Artículo › revisión exhaustiva
90
Citas
(Scopus)